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The eleven Fanconi anemia (FA) proteins cooperate in a novel pathway required for the repair of DNA
cross-links. Eight of the FA proteins (A, B, C, E, F, G, L, and M) form a core enzyme complex, required for the
monoubiquitination of FANCD2 and the assembly of FANCD2 nuclear foci. Here, we show that, in response to
DNA damage, Chk1 directly phosphorylates the FANCE subunit of the FA core complex on two conserved sites
(threonine 346 and serine 374). Phosphorylated FANCE assembles in nuclear foci and colocalizes with
FANCD2. A nonphosphorylated mutant form of FANCE (FANCE-T346A/S374A), when expressed in a FANCEdeficient cell line, allows FANCD2 monoubiquitination, FANCD2 foci assembly, and normal S-phase progression. However, the mutant FANCE protein fails to complement the mitomycin C hypersensitivity of the
transfected cells. Taken together, these results elucidate a novel role of Chk1 in the regulation of the FA/BRCA
pathway and in DNA cross-link repair. Chk1-mediated phosphorylation of FANCE is required for a function
independent of FANCD2 monoubiquitination.
Fanconi anemia (FA) is an inherited cancer susceptibility
disorder resulting from germ line disruption of 1 of 11 FA
genes (10). The FA proteins cooperate in a common cellular
pathway, the FA/BRCA pathway, and disruption of this pathway results in chromosome instability and mitomycin C
(MMC) hypersensitivity. Eight of the FA proteins (A, B, C, E,
F, G, L, and M) are assembled in a multifunctional FA core
complex (complex 1) (22). The complex contains a translocase
activity, encoded by the FANCM gene, which is required for its
interaction with chromatin (20, 21). The complex also has a
monoubiquitin E3 ligase activity, encoded by the FANCL gene,
(19) and interacts with a novel E2 ubiquitin (Ub) conjugating
enzyme (14). The putative substrate of the Ub ligase is the
FANCD2 protein. Monoubiquitinated FANCD2 functions in a
downstream complex (complex 2) containing FANCD1/
BRCA2 (11, 29). The role of FANCD2-Ub in cross-link repair
remains unknown.
FANCD2 monoubiquitination occurs during normal S-phase
progression (28) or in response to DNA damage (5). ATR-defective (Seckel) cells (1) are defective in the DNA damage-inducible monoubiquitination of FANCD2 and FANCD2 nuclear foci
assembly. ATR activates the checkpoint kinase, Chk1 (13, 31, 32),
suggesting that Chk1 may play a role in the FA/BRCA pathway.
Consistent with this model, disruption of Chk1 by small interfering RNA (siRNA) or by small-molecule inhibitors (12, 15) results
in DNA cross-linker hypersensitivity and chromosome instability,
a phenotype reminiscent of FA cells (2). In this paper, we address
the role of Chk1 in the regulation of the FA/BRCA pathway.

MATERIALS AND METHODS
Cell culture. HeLa cells, U2OS cells, GM0637 cells, and HEK293T cells were
grown in Dulbecco’s modified Eagle’s medium supplemented with 15% heatinactivated fetal calf serum in a humidified 5% CO2 incubator at 37°C. DF1179
(FA-E) fibroblasts derived from an FA-E patient were cultured in Chang medium (Irvine Scientific) (generously provided by Akiko Shimamura, Children’s
Hospital, Harvard Medical School, Boston, MA). Epstein-Barr virus-transformed lymphoblasts EUFA130 (FA-E) were maintained in RPMI 1640 medium
with 15% fetal calf serum.
Generation of DNA damage. Cells were UV irradiated with a Stratalinker
(Stratagene) at 50% to 70% confluence without any medium after being washed
with phosphate-buffered saline (PBS) once in a 100-mm dish without the lid.
After UV irradiation, fresh medium was added, and cells were continuously
cultured for the indicated time before lysis. Gamma irradiation was delivered
using a Gammacell 40 apparatus (MDS Nordion). For MMC (Sigma) treatment,
cells were continuously exposed to the drug for the indicated time before lysis.
MMC sensitivity assays of human fibroblasts and lymphoblasts were performed
essentially as described previously with the modifications given below (5, 7).
Human fibroblasts and lymphoblasts were seeded in duplicate in 96-well microplates at a density of 1,000 cells/well in appropriate medium. MMC was added at
a final concentration of 0 to 200 M. Cells were then incubated at 37°C in a 5%
CO2 incubator for 5 days, and cell survival was then determined by staining
nucleic acids with a proprietary dye (CyQUANT; Molecular Probes) and subsequently analyzed by a fluorescence microplate reader according to the manufacturer’s protocol.
Plasmids and purification of recombinant proteins. Human FANCE cDNA (3)
(generously provided by J. deWinter and H. Joenje, Free University Medical Center,
Amsterdam, The Netherlands) was subcloned into the retroviral vector pMMP-puro
(24) by adding the FLAG tag at the amino terminus of FANCE to generate pMMPpuro-FLAG-FANCE. Specific single and double mutations (pMMP-FLAG-T346A,
pMMP-FLAG-S374A, and pMMP-FLAG-T346A/S374A [TS/AA]) were introduced by using a QuikChange site-directed mutagenesis kit (Stratagene) according
to the manufacturer’s protocol. For construction of pGEX-FANCE consisting of
residues 332 to 365 [pGEX-FANCE(332–365)], pGEX-FANCE(349–382), and
pGEX-FANCE(332–382), PCR products of the corresponding fragments were ligated to the EcoRI/NotI sites of the plasmid pGEX4T-1 (Pharmacia). The cDNAs
of FANCE(T346A), FANCE(S374A), and the double mutant FANCE(TS/AA)
were produced with a QuikChange site-directed mutagenesis kit (Stratagene). A
recombinant FANCE (consisting of residues 149 to 536) wild-type (rFANCEwt)
construct was cloned to the EcoRI/HindIII sites of pET32a-PPS vector (Novagen).
For the recombinant double mutant protein FANCE(rTS/AA), the fragment consisting of residues 149 to 536 with the changes T346A and S374A was produced by
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min. Following washing with PBS, cells were resuspended in PBS containing 25
ml/g of propidium iodide (Sigma) and 0.1 mg/ml of RNase A (Sigma) prior to
fluorescence-activated cell sorter analysis using a Becton Dickinson FACSCalibur flow cytometer. Cell death was measured as the sub-G1 (less than 2N
DNA content) population.
In vivo ubiquitination assay. U2OS cells stably expressing empty vector,
FLAG-FANCEwt, and FLAG-TS/AA were transfected with pMT123 (HA-Ub)
using FuGENE6 (Roche) as described previously (29). After 48 h of transfection,
cells were treated with UV (60 J/m2) and incubated for 2 h; then cells were lysed
in 100 l of denaturation buffer (20 mM Tris HCl [pH 7.5], 50 mM NaCl, 1%
SDS) and heated to 95°C for 10 min. Debris was removed by centrifugation. The
remaining portions of denatured lysates were diluted to 1.1 ml in TBS buffer (20
mM Tris HCl [pH 7.5], 50 mM NaCl, 1% Triton X-100) supplemented with
protease and phosphatase inhibitors (10 g/ml pepstatin A, 2 g/ml aprotinin, 10
g/ml leupeptin, 1 mM phenylmethylsulfonyl fluoride, 1 mM sodium orthovanadate, 25 mM NaF) and incubated for 30 min on ice to allow renaturation. Lysates
were precleared with protein G-agarose beads (Sigma) for 30 min at 4°C.
Cleared extracts were then incubated with anti-FLAG antibody overnight on the
shaker at 4°C before protein G-agarose beads were added. The immunoprecipitated materials were washed four times with Tris-buffered saline buffer and
separated by SDS-PAGE, followed by Western blotting with the indicated antibodies.

RESULTS
Phosphorylation of FANCE on two conserved sites is required for MMC resistance. To examine the role of Chk1 in
the FA/BRCA pathway, we scanned the primary amino acid
sequence of eleven FA proteins (A, B, C, D1, D2, E, F, G, L,
M, and J) for the Chk1 phosphorylation consensus sequence
[⫺7(Leu/Arg) ⫺6(Xaa) ⫺5(Leu/hydrophobic/Arg) ⫺4(basic/
Val) ⫺3(Arg/Lys) ⫺2(Tyr/Xaa) ⫺1(Xaa) Ser/Thr ⫹1(Phe/
Met/hydrophobic), where Xaa indicates no strong amino acid
preference] (23). Two highly conserved phosphorylation sites
were identified in the carboxy terminal region of the FANCE
protein, Thr346 and Ser374 (Fig. 1A). To determine the functional relevance of these putative phosphorylation sites, we mutated each site, either individually or in combination, within the
full-length FANCE protein. Patient-derived FA-E cell lines,
EUFA130 lymphoblasts and DF1179 fibroblasts, were retrovirally transduced with the cDNA encoding either wt FANCE
(FLAG-FANCEwt), mutant FANCE (carrying FLAG-T346A
or FLAG-S374A), or the double point mutant FANCE carrying the FLAG tag [FLAG-FANCE(TS/AA)] (Fig. 1B) (see
Fig. S1 in the supplemental material). While cells expressing
FLAG-FANCEwt were MMC resistant, cells expressing the
double mutant FLAG-FANCE(TS/AA) remained hypersensitive to MMC.
We examined the ability of the FANCE mutant proteins to
restore FANCD2 monoubiquitination (Fig. 1C). As previously
described (3, 27), FLAG-FANCEwt restored FANCD2 monoubiquitination (Fig. 1C, lanes 6 to 10), and DNA damage generated by ionizing radiation (IR) further activated FANCD2 monoubiquitination. The double mutant FLAG-FANCE(TS/AA) also
restored monoubiquitination of FANCD2. Cells expressing
FLAG-FANCE(TS/AA) had elevated basal levels of FANCD2
monoubiquitination (Fig. 1C, compare lanes 6 and 11) and failed
to exhibit further FANCD2 monoubiquitination following DNA
damage (Fig. 1C, lanes 11 to 15).
We next determined the assembly of FANCD2 nuclear foci
in the FA-E cells expressing the double mutant FLAGFANCE(TS/AA) (Fig. 1D and E). Both FLAG-FANCEwt and
FLAG-FANCE(TS/AA) restored FANCD2 foci formation
(Fig. 1D). Cells expressing FLAG-FANCE(TS/AA) had in-
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PCR using pMMP-FLAG-TS/AA as a template, and the product was cloned to the
EcoRI/HindIII sites of pET32a-PPS vector. All constructs and mutants were confirmed by DNA sequencing.
Glutathione S-transferase (GST)–FANCE constructs spanning the FANCE
sequence of residues 332 to 382 were expressed in E. coli BL21 cells. A GSTCdc25C(200–256) construct (containing residues 200 to 256 of Cdc25C) (generously provided by Michael Yaffe, Massachusetts Institute of Technology, Boston,
MA) was used as a positive control for in vitro kinase assays. The GST fusion
proteins were then purified on glutathione S-Sepharose beads and used as substrates in the in vitro kinase reaction. The rFANCEwt and double mutant
FANCE(rTS/AA) proteins were expressed and induced in E. coli BL21(DE3)RP
cells and then were purified by metal affinity chromatography using polyhistidine
(His) binding HiTrap chelating HP columns (Pharmacia). After recombinant
proteins were eluted from the column by incubation with precision protease to
cleave the N-terminal His tag sequence, further purification by HiTrapQFF
anion exchange columns (Pharmacia) and S-200 gel filtration columns was performed.
Retroviral infection. Production of pMMP retroviral supernatants and infection of fibroblasts or lymphoblasts were performed as previously described
(5, 27).
Generation of anti-FANCE, anti-pT346-FANCE, and anti-pS374-FANCE antibodies. A rabbit polyclonal antibody against FANCE was generated by
Invitrogen (Zymed) using a C-terminal peptide of residues 521 to 536 of
FANCE as an antigen source. For generation of phosphospecific antibodies
(anti-pT346-FANCE and anti-pS374-FANCE), rabbits were immunized with
a keyhole limpet hemocyanin-conjugated FANCE phosphopeptide, SDLGL
LRLC(pT)WL or phosphopeptide LFLGRIL(pS)LTSS, derived from amino
acids 337 to 348 or 367 to 378 of FANCE, respectively. Antibodies were
affinity purified using the corresponding phosphorylated and nonphosphorylated peptide-conjugated gels.
Immunoblotting. Cells were lysed, and whole-cell extracts were subjected to
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), transferred to nitrocellulose membranes, and subjected to Western blot analysis (5).
The following antibodies were used: anti-FANCD2 (FI-17) (Santa Cruz Biotechnology), antihemagglutinin (anti-HA) (HA.11; Babcock), anti-FLAG (M2)
(Sigma), anti-␤-tubulin (Santa Cruz Biotechnology), anti-phopsho-317-Chk1
(Cell Signaling Technology), and anti-Chk1(G-4) (Santa Cruz Biotechnology).
In vitro kinase assay. The GST fusion proteins of FANCE (2 g) were
incubated with purified recombinant Chk1 (100 ng) (Upstate Technology) in 30
l of kinase buffer (20 mM Tris HCl, 10 mM MgCl2, 10 mM MnCl2, 1 mm
dithiothreitol, 10 M ATP) containing 10 Ci of [␥32P]ATP. Kinase reactions
were incubated for 30 min at 30°C, stopped by the addition of SDS sample buffer,
boiled for 5 min, and then analyzed by SDS-PAGE and X-ray film autoradiography. In vitro kinase assays were performed using GST-Cdc25C(200–256) and
GST for positive and negative controls. Assay conditions were the same as
described above. The rFANCEwt and FANCE(rTS/AA) (3 g each) proteins
were incubated without or with 100 ng of purified recombinant Chk1, Chk2,
mitogen-activated protein kinase-activated protein kinase 2 (MAPKAPK2; also
known as MK2) (Upstate Technology) or GST in 30 l of kinase buffer (20 mM
Tris HCl, 10 mM MgCl2, 10 mM MnCl2, 1 mm dithiothreitol, 1 mM ATP) for 30
min at 30°C; the kinase reaction was stopped by the addition of SDS sample
buffer, boiled for 5 min, and then analyzed by SDS-PAGE, followed by Western
blotting with anti-pT346-FANCE, anti-pS374-FANCE antibodies.
Immunoprecipitation. Immunoprecipitation was performed as previously described (29).
SiRNA and transfection. Expression of targeted genes was knocked down by
transient expression of siRNA directed against green fluorescent protein (GFP)
(5⬘-AACACTTGTCACTACTTTCTC-3⬘), Chk1 (5⬘-AAGAAGCAGTCGCAG
TGAAGA-3⬘), and ATR (5⬘-CAGGCACTAATTGTTCTTCAA-3⬘). Transfection of siRNAs was performed using Hiperfect (QIAGEN) according to the
manufacturer’s protocol. At 72 h of transfection, cells were exposed to DNA
damage.
Immunofluorescence microscopy. Preparation of cells for immunofluorescence microscopy was performed as described previously (29). Lymphoblast cell
lines were grown on culture slides coated with poly-D-lysine (BD Bioscience) to
promote adhesion for 36 h before treatment. Images were acquired using an
Axioplan 2 imaging microscope (Carl Zeiss) equipped with a digital camera and
processed using Openlab software.
Fluorescence-activated cell sorter analysis. G2/M checkpoint analysis and
DNA replication were performed as described previously (30). To detect a
sub-G1 population, cells were harvested at 0, 24, 48, and 72 h after MMC (160
ng/ml) treatment, washed with PBS, fixed in 70% ethanol (106 cells per ml) for
at least 1 h at 4°C, and permeabilized in 0.25% Triton X-100–PBS at 4°C for 15
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FIG. 1. Two highly conserved Chk1 phosphorylation sites on FANCE. (A) Alignment of sequences surrounding the phosphorylation motif for
Chk1 [R-X-X-(S/T)] in human FANCE with FANCE sequences in other organisms. (B) Complementation of MMC sensitivity of an FA-E
lymphoblast cell line, EUFA130, with empty vector (pMMP), pMMP-FLAG-FANCE, pMMP-FLAG-T346A, pMMP-FLAG-S374A, and pMMP-
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stably expressing vector and the double mutant FLAGFANCE(TS/AA) (Fig. 2D, left panel). Interestingly, the phosphorylated FANCE protein, detected by anti-pT346 antibody,
assembled in DNA damage-inducible nuclear foci (Fig. 2D; see
also Fig. S2A and B in the supplemental material). UV also
activated pT346-FANCE foci in HeLa cells, and siRNA directed against ATR or Chk1 decreased the UV-inducible
pT346-FANCE foci (Fig. 2D and E). Pretreatment with Chk1
inhibitors (Gö6976 or SB218078) decreased the pT346FANCE foci formation after UV exposure (see Fig. S2C and D
in the supplemental material).
siRNA knockdown of Chk1 results in an elevated basal level
of FANCD2 monoubiquitination and FANCD2 foci. We next
examined the effect of siRNA knockdown of Chk1 on
FANCD2 monoubiquitination and FANCD2 focus formation
after DNA damage (Fig. 3). siRNA knockdown of Chk1 resulted in an elevated basal level of FANCD2 focus formation
(Fig. 3A) and FANCD2 monoubiquitination (Fig. 3B, lane 4).
Monoubiquitination and nuclear focus formation of FANCD2
were not further increased following DNA damage (Fig. 3B,
lanes 4 to 6, and C). These results indicate that the disruption
of Chk1 activity mimics the cellular phenotype of the double
mutant FANCE(TS/AA).
Colocalization of FANCD2 foci and pT346-FANCE foci. We
next examined the assembly of pT346-FANCE foci and
FANCD2 foci following DNA damage (Fig. 4). Untreated
HeLa cells exhibited no pT346-FANCE foci or FANCD2 foci
(Fig. 4A). DNA damage from UV light activated the phosphorylation of FANCE on T346 and foci formation by 30 min, and
these foci were no longer observed after 8 h. FANCD2 foci
began to accumulate at 30 min after UV and peaked at 8 h.
The kinetics of pT346-FANCE focus formation and FANCD2
focus formation are shown graphically in Fig. 4B. Double staining revealed that pT346-FANCE foci and FANCD2 foci colocalize (Fig. 4C) but exhibit distinct kinetics (Fig. 4B).
Chk1-mediated phosphorylation of FANCE is required for
MMC resistance but not required for DNA replication or
normal cell cycle progression. Recent studies indicate that the
FA core complex has additional replication and checkpoint activities which are discrete from FANCD2 monoubiquitination (18).
To determine whether phosphorylation of FANCE by Chk1 is
required for normal S-phase progression, we compared the ability
of FLAG-FANCEwt or the double mutant FLAG-FANCE(TS/
AA) to restore DNA replication and S-phase progression (Fig. 5
A and B). After 24 h of MMC treatment, FA-E cells (EUFA130)
expressing either FLAG-FANCEwt) or FLAG-FANCE(TS/AA)
were equally competent for DNA replication and did not accumulate in the late S and G2 cell cycle phase. As expected, FA-E
cells containing the empty vector arrested and accumulated in late

FLAG-TS/AA. The indicated retroviral supernatants were generated and used to transduce EUFA130 cells. Puromycin-resistant cells were
selected, and MMC sensitivity was determined as described in Materials and Methods. The values shown are the means ⫾ standard deviations from
four separate experiments. (C) Restoration of monoubiquitination of FANCD2. The indicated stably transduced FA-E lymphoblast cell lines were
either untreated or exposed to IR at different doses, as indicated, and harvested after 6 h. Western blotting was performed with anti-FANCD2 or
anti-FLAG antibodies. L/S ratio, ratio of monoubiquitinated to nonubiquitinated FANCD2. (D) Restoration of FANCD2 nuclear focus formation.
EUFA130 lymphoblasts stably expressing FLAG-FANCEwt (EUFA130⫹FLAG-FANCE) and the double mutant FLAG-FANCE(TS/AA)
(EUFA130⫹FLAG-TS/AA) were either untreated or treated with IR (10 Gy) and fixed 6 h later; immunofluorescence was determined using
anti-FANCD2 (FI-17) antibody. Magnification, ⫻630. (E) Quantification of FANCD2 foci. Cells with more than four distinct foci were counted
as positive; 200 cells/sample were analyzed. The values shown are the means ⫾ standard deviations from three separate experiments. Vec, empty
vector.
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creased basal levels of FANCD2 foci and failed to upregulate
FANCD2 foci after DNA damage (Fig. 1E), thus correlating
with FANCD2 monoubiquitination levels (determined by
Western blotting) (Fig. 1C). Taken together, these results suggest that phosphorylation of Thr346 and Ser374 on FANCE is
not required for FANCD2 monoubiquitination and foci formation but is required for MMC resistance.
Phosphorylation of FANCE by Chk1 in vitro and in vivo. To
demonstrate whether Chk1 directly phosphorylates FANCE,
we examined phosphorylation of the two highly conserved
threonine and serine residues by Chk1 in vitro. We generated
GST peptide fusion proteins containing different regions of
FANCE (Fig. 2A, left panel). Three GST peptide fusion proteins containing either Thr346 or Ser374 or both residues and
consisting of the wt sequence of residues 332 to 365, 349 to 382,
or 332 to 382 (but not the GST fusion proteins with single or
double mutations of Thr to Ala or Ser to Ala) were phosphorylated by Chk1 in vitro (Fig. 2A, right panel).
To further study the phosphorylation of FANCE on T346
and S374 by Chk1, we raised rabbit polyclonal antisera against
FANCE peptides containing the putative phosphorylated residues, SDLGLLRLCpT(346)WL (anti-pT346) or against LFL
GRILpS(374)LTSS (anti-pS374). Purified rFANCEwt or the
double mutant FANCE(rTS/AA) protein was incubated with
Chk1 or with the two related checkpoint kinases, Chk2 and
MAPKAP2 (17) in vitro (Fig. 2B). The anti-phosphospecific
antibodies for FANCE (anti-pT346 and anti-pS374) specifically recognized the rFANCEwt protein phosphorylated by
Chk1 in vitro (Fig. 2B, lane 3). rFANCEwt was not phosphorylated by Chk2 or MAPKAP2 in vitro (Fig. 2B, lanes 4 and 5).
The specificity of the antibodies was demonstrated by the lack
of reactivity with the double mutant protein FANCE(rTS/AA)
and GST (Fig. 2B, lanes 6 to 15).
We then determined whether FANCE is phosphorylated in
vivo following DNA damage (Fig. 2C). Using anti-pT346 and
anti-pS374, we immunoblotted FLAG-FANCE immune complexes from FA-E cells stably expressing FLAG-FANCEwt or
the double mutant FLAG-FANCE(TS/AA). Following cellular
exposure to UV light, a potent activator of the FA/BRCA
pathway (4), the anti-pT346 and anti-pS374 antisera detected
the FLAG-FANCEwt but not FLAG-FANCE(TS/AA). Taken
together, these results confirm the specificity of the antibodies
and the DNA damage-inducible phosphorylation of these two
residues.
We next used immunofluorescence to demonstrate the in
vivo phosphorylation of FANCE by Chk1. The anti-pT346
antiserum detected activated FANCE protein in corrected
FA-E lymphoblasts (Fig. 2D, EUFA130⫹FLAG-FANCE) after cellular exposure to DNA damage but not in FA-E cells
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FIG. 2. Phosphorylation of FANCE by Chk1 in vitro and in vivo. (A) GST-FANCE peptide fusion proteins, containing the indicated regions
of FANCE, were generated and used as substrates for in vitro kinase assays; the threonine (346) and/or serine (374) residues that were mutated
to alanine are shown (left panel). GST-FANCE peptide fusion proteins were incubated with [␥-32P]ATP and purified recombinant Chk1 as
described in Materials and Methods. The reaction was stopped by the addition of SDS sample buffer before analysis by SDS-PAGE and
autoradiography (right panel). The GST-Cdc25C(200–256) peptide fusion protein and GST were used as positive and negative control substrates,
respectively, for Chk1 to demonstrate efficient in vitro kinase assays. (B) In vitro kinase assays using GST, purified recombinant Chk1, Chk2, or
MAPKAPK2 (MK2) to phosphorylate the recombinant proteins (containing residues 149 to 536) rFANCEwt and the double mutant FANCE(rTS/
AA) were performed and analyzed by SDS-PAGE, followed by immunoblotting with the pT346-FANCE and pS374-FANCE antibodies. The
GST-Cdc25C(200–256) peptide fusion protein and GST were used as positive and negative control substrates, respectively, for Chk1, Chk2, and
MK2 to demonstrate efficient in vitro kinase assays (data not shown). (C) Chk1 phosphorylates FANCE in vivo. EUFA130 lymphoblasts were
stably expressed with empty vector (Vec), FLAG-FANCEwt, and FLAG-FANCE(TS/AA) as indicated. Cells were either untreated or treated with
UV (60 J/m2); after 3 h, immunoprecipitation was performed using anti-FLAG antibody, followed by SDS-PAGE and then Western blotting with
anti-pT346-FANCE and anti-pS374-FANCE phosphospecific antibodies and anti-FLAG antibody. (D) EUFA130 lymphoblasts stably expressing
empty vector (EUFA130⫹Vec) and FLAG-FANCEwt (EUFA130⫹FLAG-FANCE) were either untreated or treated with UV (60 J/m2) and fixed
2 h later; immunofluorescence was performed using anti-pT346-FANCE antibody (left panel). Magnification, ⫻630. HeLa cells were transiently
transfected with siRNA targeted against GFP (control), Chk1, or ATR. After 72 h of transfection, cells were either untreated or treated with UV
(60 J/m2) and incubated for 2 h before fixation; immunofluorescence was performed using anti-pT346-FANCE antibody (right panel). Magnifi-
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S and G2 phase and demonstrated decreased DNA synthesis (Fig.
5A and B). Moreover, the double mutant FLAG-FANCE(TS/
AA) stabilized the FA core complex and restored FANCD2
monoubiquitination (Fig. 1C; see also Fig. S3A in the supplemental material).
We next tested whether the double mutant of FANCE could
prevent MMC-mediated cell death when expressed in the
FA-E cell line. Cell death results in nuclear fragmentation (the
sub-G1 population), and this was assessed by flow cytometry
following MMC treatment. As shown in Fig. 5C, equivalent
levels of sub-G1 cells were present in FA-E cells stably expressing empty vector and the double mutant FLAG-FANCE(TS/
AA) following MMC treatment. In contrast, FA-E cells corrected with FLAG-FANCEwt demonstrated a significantly
lower percentage of cells with fragmented nuclei. These results
demonstrate that the intact FA core complex containing
FLAG-FANCE(TS/AA) can correct the cell cycle abnormalities of FA-E cells but cannot confer resistance to MMC, con-

firming that Chk1-mediated phosphorylation of FANCE is required for cross-linker resistance (Table 1).
Chk1-mediated phosphorylation of FANCE promotes FANCE
degradation. The disappearance of pT346-FANCE foci after
DNA damage (Fig. 4A) suggested that FANCE may undergo
regulated proteolysis. To test this hypothesis, we examined the
cellular levels of FANCE following UV damage (Fig. 6A);
after only 30 min, Chk1 activation and FANCD2 monoubiquitination were observed (Fig. 6A, lane 2). By 4 to 6 h,
FANCD2 monoubiquitination was maximal, and FANCE levels had decreased (Fig. 6A, lanes 4 to 6); FANCE degradation
was also observed in a UV dose-dependent manner (data not
shown).
We synchronized HeLa cells at the G1/S boundary with a
double-thymidine block and released the cells into S phase for
1 h before DNA damage treatment. The level of FANCE
protein was significantly decreased when a genotoxic stress
(UV, hydroxyurea [HU], MMC, or cisplatin) was delivered to

cation, ⫻400. (E) Quantification of pT346-FANCE foci. Cells with more than four distinct foci were counted as positive; 100 cells/sample were
analyzed. The values shown are the means ⫾ standard deviations from three separate experiments. The formation of pT346 FANCE foci with the
treatment of UV (60 J/m2) was strongly decreased in HeLa cells in which ATR or Chk1 had been suppressed with siRNA.
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FIG. 3. Knockdown of Chk1 results in an increased basal level of FANCD2 foci assembly. (A and B) HeLa cells were transfected with siRNAs
targeted against GFP (control) or Chk1. After 72 h of transfection, cells were treated with UV (60 J/m2) and incubated for 3 h or 6 h before fixation
and lysis; immunofluorescence was performed using anti-FANCD2 antibody. Magnification, ⫻400 (A) Whole-cell extracts were analyzed by
Western blotting with the indicated antibodies. An anti-␤-tubulin blot was used as a loading control (B). (C) Quantification of FANCD2 foci. Cells
with more than four distinct foci were counted as positive; 200 cells/sample were analyzed. The values shown are the means ⫾ standard deviations
from three separate experiments.
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cells undergoing DNA replication (Fig. 6B, lanes 2 to 5). UVinducible FANCE degradation was also observed in other cell
lines, including U2OS, GM0637, and HEK293T cells (see Fig.
S3B in the supplemental material).
We then tested whether Chk1-dependent phosphorylation
regulates FANCE stability (Fig. 6C). We examined FA-E
(EUFA130) cells stably expressing FLAG-FANCEwt or the
double mutant FLAG-FANCE(TS/AA). After UV treatment,
FLAG-FANCEwt was degraded (Fig. 6C, compare lanes 3 and
4), but FLAG-FANCE(TS/AA) was stable (Fig. 6C, compare
lanes 5 and 6).
We next examined the role of the Ub-proteasome pathway in
the degradation of FANCE (Fig. 6D). Cells were treated with UV
in the absence or presence of the proteasome inhibitor, MG132.
MG132 treatment blocked the UV-inducible degradation of
FANCE (Fig. 6D, lane 3). We transiently transfected a cDNA
encoding an HA-Ub construct into U2OS cells stably expressing
FLAG-FANCEwt or the double mutant FLAG-FANCE(TS/
AA). FLAG-tagged FANCE was immunoprecipitated and immunoblotted with anti-HA and anti-FLAG antibodies. Following
UV exposure, the high-molecular-weight ladder of polyubiquitinated products of the FLAG-FANCEwt was enhanced by UV

exposure (Fig. 6E, lane 8), which does not present in cells expressing empty vector or FLAG-FANCE(TS/AA) (Fig. 6E, lanes
7 and 9, respectively), indicating that, following DNA damage,
FANCE phosphorylation precedes its polyubiquitination. Taken
together, these results indicate that the Chk1-mediated phosphorylation of FANCE promotes the Ub-mediated degradation of
FANCE. The specific E3 Ub ligase complex required for FANCE
degradation remains unknown.

DISCUSSION
Our results elucidate several properties of FANCE in the
FA/BRCA pathway. FANCE is assembled in the FA core
complex and promotes the monoubiquitination of FANCD2
(Fig. 6F). FANCE is phosphorylated by Chk1 at an early stage,
within 30 min following DNA damage; however, Chk1-dependent phosphorylation of FANCE is not required for FANCD2
monoubiquitination and nuclear focus formation since the nonphosphorylated, double mutant FANCE(TS/AA) is competent
for restoring FANCD2 monoubiquitination and FANCD2 foci
in the FA-E-deficient cells. Therefore, phosphorylation of
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FIG. 4. Colocalization of pT346-FANCE foci and FANCD2-Ub foci after DNA damage. (A) The kinetics of pT346-FANCE foci and FANCD2
foci were followed after DNA damage. HeLa cells were either untreated or treated with UV (60 J/m2) and incubated for different periods of time
(30 min, 2 h, 4 h, 6 h, or 8 h) as indicated before fixation; immunofluorescence was performed using anti-pT346-FANCE and anti-FANCD2 (FI-17)
antibodies. Magnification, ⫻400. (B) Cells with more than four distinct foci were counted as positive; 200 cells/sample were analyzed. The values
shown are the means ⫾ standard deviations from three separate experiments. (C) After 4 h of UV irradiation, colocalization of pT346-FANCE
foci and FANCD2 foci in HeLa cells is shown. Magnification, ⫻630.
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FANCE by Chk1 is required for an unknown function independent of FANCD2 monoubiquitination.
Failure to phosphorylate FANCE, as in Chk1-depleted cells
or in cells expressing the FANCE(TS/AA) mutant protein,
results in an elevated basal level of FANCD2 monoubiquitination and nuclear foci. This failure also results in persistent
cellular hypersensitivity to MMC. The elevated basal level of

FANCD2 foci may result from increased spontaneous endogenous DNA damage or from failure of the mutant FANCE
protein to function independently of FANCD2 monoubiquitination. Paradoxically, our previous studies have shown that
ATR inactivation has little or no effect on the basal level of
FANCD2 monoubiquitination (1). Our findings are consistent
with recent studies (S. J. Boulton, personal communication)

TABLE 1. Characterization of FA-E cells stably expressing empty vector, FANCEwt, or the double mutant FANCE(TS/AA)
Characterization of EUFA130 cells expressing:
Feature

MMC sensitivity
FA core complex assembly
FANCD2 monoubiquitination
DNA damage-inducible FANCD2 monoubiquitination
Cell cycle progression after MMC treatment for 24 h
Relative percentage of sub-G1 population after MMC
treatment

Empty vector

FLAG-FANCEwt

FLAG-FANCE(TS/AA)

Sensitive
⫺
⫺
⫺
Late S/G2 accumulation
High

Resistant
⫹
⫹
⫹
Normal
Low

Sensitive
⫹
⫹
⫺
Normal
High
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FIG. 5. FANCE phosphorylation by Chk1 does not correct MMC-mediated cell death but corrects cell cycle progression and promotes DNA
synthesis following MMC treatment. (A) FA-E cells stably expressing wt FANCE (EUFA130⫹FLAG-FANCEwt) or the double mutant of FANCE
(EUFA130⫹FLAG-TS/AA) do not accumulate in the late S/G2 phase of the cell cycle after 24 h of MMC treatment compared to cells stably
expressing empty vector (EUFA130⫹Vec). The values shown are the means ⫾ standard deviations from three separate experiments. (B) FA-E
cells stably expressing empty vector (EUFA130⫹Vec) have decreased DNA synthesis after 24 h of MMC 160 ng/ml treatment compared to FA-E
cells stably expressing wt FANCE (EUFA130⫹FLAG-FANCEwt) or the double mutant of FANCE (EUFA130⫹FLAG-TS/AA). The values
shown are the means ⫾ standard deviations from three separate experiments. (C) FA-E cells stably expressing the double mutant of FANCE
(EUFA130⫹FLAG-TS/AA) or empty vector (EUFA130⫹Vec) demonstrate a higher percentage of sub-G1 cells after 48 and 72 h following MMC
(160 ng/ml) treatment than cells expressing wt FANCE. Values shown are the means ⫾ standard deviations from three separate experiments.
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which indicate that the depletion of ATR and Chk1 may have
opposite effects on the FA/BRCA pathway function. Taken
together, our results from this study and our previous work (1)
suggest that ATR and Chk1 have both overlapping and distinct
functions in the regulation of the FA/BRCA pathway.

The function of FANCE phosphorylation by Chk1 in the
FA/BRCA pathway remains unknown, and several possible
mechanisms exist. First, pT346-FANCE may participate with
FANCD2-Ub in recruiting other DNA repair proteins to sites of
DNA cross-link repair. Second, pT346-FANCE may be required
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FIG. 6. FANCE phosphorylation by Chk1 promotes its degradation. (A) HeLa cells were either untreated or treated with UV irradiation at 60 J/m2
and incubated for different periods of time as indicated before lysis. Whole-cell extracts were immunoblotted with the indicated antibodies. An
anti-␤-tubulin blot was used as a loading control. (B) HeLa cells were synchronized by a double-thymidine block and then released into S phase. One
hour after release, the cells were either untreated (Control) or treated with UV (60 J/m2, 15 h), HU (2 mM, 24 h), MMC (160 ng/ml, 24 h), or cisplatin,
(10 M, 24 h). Whole-cell extracts were analyzed by Western blotting with the indicated antibodies. An anti-␤-tubulin blot was used as a loading control.
(C) EUFA130 lymphoblasts were stably expressed with pMMP (empty vector [Vec]), FLAG-FANCEwt, or FLAG-FANCE(TS/AA) (the double mutant)
as indicated. Cells were either untreated or treated with UV (60 J/m2); after 8 h, whole-cell extracts were analyzed by Western blotting with the indicated
antibodies. An anti-␤-tubulin blot was used as a loading control. (D) U2OS cells were either untreated or treated with UV (60 J/m2) and incubated for
3 h with or without the addition of 25 M MG132 to the indicated samples during the final 2 h in cell culture. Whole-cell extracts were analyzed by
Western blotting with the indicated antibodies. An anti-␤-tubulin blot was used as a loading control. (E) FANCE ubiquitination in vivo. U2OS stably
expressing empty vector (a), FLAG-FANCEwt (b), or and FLAG-FANCE(TS/AA) (c) were transiently transfected without or with a cDNA encoding
HA-Ub; after 48 h of transfection, cells were untreated or treated with UV (60 J/m2) and incubated for 2 h before cells were lysed in SDS denaturation
buffer. FLAG-FANCEwt and the double mutant protein were isolated by anti-FLAG antibody immunoprecipitation. Immune complexes were run on
SDS-PAGE gels and immunoblotted with anti-HA or anti-FLAG antibodies. (F) Schematic model showing the activation of the FA/BRCA pathway by
the ATR-Chk1 pathway. DNA damage or replication arrest (MMC, UV, IR, or HU) activates the ATR-dependent phosphorylation of FANCD2 (6) and
the Chk1-dependent phosphorylation of FANCE. Both monoubiquitinated FANCD2 and phosphorylated FANCE are required for MMC resistance. A
nonubiquitinated mutant of FANCD2 (K561R) or the nonphosphorylated mutant FANCE(TS/AA) fails to correct MMC hypersensitivity.
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to stabilize FANCD2-Ub or to carry it to a specific nuclear compartment where cross-link repair occurs. Third, phosphorylation
of FANCE may be required for its timed degradation, and this
degradation may be essential for the proper function of the FA/
BRCA pathway. Consistent with this notion, pT346-FANCE foci
disappear 8 h after DNA damage, while FANCD2 foci persist.
Also consistent with this hypothesis, phosphorylation of FANCE
by Chk1 promotes its degradation. The timed degradation of
FANCE may be a negative regulatory mechanism for switching
off the FA/BRCA pathway after the completion of DNA repair.
The cellular role of phosphorylation of FANCE and
FANCD2-Ub in cross-link repair remains an important unanswered question for the FA research field.
Based on these observations, FANCE may have a dual regulatory role in the FA/BRCA pathway. On the one hand,
FANCE positively regulates the assembly of the FA core complex (A/B/C/E/F/G/L/M complex) and tethers the FANCD2
protein to the FA core complex. FA complex assembly promotes the basal levels of monoubiquitination of FANCD2 observed during S-phase progression. On the other hand,
FANCE may also negatively regulate the FA/BRCA pathway.
In response to DNA damage or replication arrests, Chk1mediated phosphorylation of FANCE may trigger its degradation. The timed degradation of FANCE may dissociate
FANCD2 from the FA core complex and thus prevent further
FANCD2 monoubiquitination.
The double mutant FANCE(TS/AA) protein functions normally in other aspects of the FA/BRCA pathway. The mutant
protein stabilizes the FA core complex and corrects the DNA
replication and cell cycle abnormalities observed in FA-E cells
after 24 h of MMC treatment. These results suggest that the
basal levels of FANCD2 monoubiquitination, observed in
FA-E cells stably expressing FANCE(TS/AA), are sufficient to
correct FA-associated cell cycle abnormalities after DNA damage but that the downstream function of FANCE is required to
prevent cell death.
The failure of the FA core complex containing the
FANCE(TS/AA) mutant protein to correct FA-E cells is consistent with other recent studies. Matsushita et al. (18) demonstrated that a FANCD2-monoubiquitin fusion protein
corrects the DNA cross-linker hypersensitivity of FANCD2deficient cells but not of core complex-deficient cells. These
authors concluded that the FA core complex has additional
functions beyond the monoubiquitination of FANCD2. The
Chk1-mediated phosphorylation of FANCE may be required
for one of these additional functions.
FANCE joins a growing list of proteins that are phosphorylated by Chk1 following DNA damage. Chk1 phosphorylates
the phosphatase Cdc25A (25), thereby promoting its immediate degradation by a Cul1/␤-TCRP-mediated mechanism (8,
16). Degradation of Cdc25A prevents dephosphorylation of
Cdc2 and arrests cell cycle progression at G1/S (8, 16). Recent
studies have identified additional substrates of the Chk1 kinase, including RAD51 (26) and MDMX1 (9). These substrates demonstrate that Chk1 can regulate checkpoint activity
(Cdc25A), DNA repair activity (FANCE and RAD51), or
transcriptional events (MDMX1). Finally, the anti-pT346
FANCE antibody described in this study may be a useful reagent in evaluating the activity of Chk1 inhibitors, a new class
of anticancer therapeutics.
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